ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, will attend Piper Jaffray & Co.’s 20th Annual Health Care Conference on Dec. 2 at The New York Palace hotel. Tony Eisenhut, president of Rheonix, will participate in a panel on infectious disease along with John Bishop, chairman and CEO, Cepheid, and Randy Rasmussen, president, BioFire Diagnostics. The discussion will take place from 10 to 11 a.m.
The panelists will discuss targeted tests, the future of the infectious-disease diagnostic market, the impact of FDA regulation on laboratory-developed tests and the declining cost of sequencing, among other current trends. Panelists will also talk about the adoption of molecular diagnostics in emerging markets, the direction of the MDx market in the U.S. and Europe and the most important features of a molecular diagnostic system.
“I am excited to represent Rheonix on this panel hosted by Piper Jaffray because we have an important tool for hospital laboratories that complements current molecular diagnostic platforms while bringing a unique and greatly needed value proposition. It’s important to share this with the public and the industry,” said Eisenhut.
At the conference, more than 160 public biotechnology, specialty pharmaceuticals, drug discovery, medical technology, medical diagnostics and devices and health care services companies will convene for interactive presentations and discussions.
Eisenhut will also highlight Rheonix’s innovative platform, the EncompassMDx™ . The EncompassMDx is a platform with unmatched versatility and affordability that performs fully automated, complex molecular assays in an easy-to-use and economical format using the Rheonix CARD® cartridge. The CARD is a cartridge the size of a smartphone that can run several biological samples through a fully integrated molecular analysis with no user intervention—it automatically manipulates the network of microfluidic pumps, valves and channels. The EncompassMDx can dramatically decrease the cost of testing, while increasing user efficiency and accuracy. Furthermore, the product’s automation, capability for high throughput and high complexity, and unique sample-to-result system will allow the platform to solve workflow inefficiencies within the diagnostic segment of the health care industry.